Table 1.

Sensitiser enhancement ratios (SER) for prostate cancer and prostate epithelial cells treated with citrate-AuNP or RALA-AuNP conjugates

	Mean SER	DEF @ 2 Gy	DEF @ 4 Gy	α	β
DU145
Radiation	–	–	–	0.15 ± 0.05	0.08 ± 0.007
Citrate-AuNP	0.9	0.9	0.85	− 0.06 ± 0.04	0.04 ± 0.01
RALA-AuNP	1.23	1.22	1.49	0.11 ± 0.07	0.03 ± 0.02
PC-3
Radiation	–	–	–	0.08 ± 0.07	0.032 ± 0.02
Citrate-AuNP	1.14	1.14	1.22	0.147 ± 0.05	0.028 ± 0.02
RALA-AuNP	1.54	1.66	2.04	0.35 ± 0.06	0.006 ± 0.02
PNT2-C2
Radiation	–	–	–	0.199 ± 0.04	0.04 ± 0.01
Citrate-AuNP	1.1	1.17	1.2	0.093 ± 0.091	0.028 ± 0.22
RALA-AuNP	0.96	0.97	1.07	− 0.045 ± 0.15	0.0053 ± 0.0039

SER represents a ratio of the area under the curve for control verses treated cells using a survival fraction baseline of 0.1. DEF provides a ratio of survival fractions for control/AuNP treated at a single fixed dose point e.g., 2 Gy and 4 Gy, the survival fractions of which are extrapolated from the LQ survival curve. Similarly, α and β values have been extrapolated from LQ survival curves